Immuron Limited (IMRN)
IMRN Stock Price Chart
Explore Immuron Limited interactive price chart. Choose custom timeframes to analyze IMRN price movements and trends.
IMRN Company Profile
Discover essential business fundamentals and corporate details for Immuron Limited (IMRN) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
9 Jun 2017
Employees
7.00
Website
https://www.immuron.com.auCEO
Steven George Lydeamore CPA,
Description
Immuron Limited, a biopharmaceutical company, researches, develops, and commercializes polyclonal antibodies in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It markets Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and reduce the symptoms of minor gastro-intestinal disorders, as well as for dietary supplement for digestive tract protection; and Protectyn, an immune supplement to maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) that is in Phase III clinical trials to reduce the risk of contracting travelers' diarrhea, as well as acts as an anti-viral activity against SARS-CoV-2; and IMM-529, which is in clinical development stage focuses on treating patients suffering from recurring clostridium difficile infection. It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and ETEC infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis. Immuron Limited was incorporated in 1994 and is based in Carlton, Australia.
IMRN Financial Timeline
Browse a chronological timeline of Immuron Limited corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 26 Feb 2026
Upcoming earnings on 7 Oct 2025
Earnings released on 29 Aug 2025
Earnings released on 28 Feb 2025
EPS came in at -$0.00 surpassing the estimated -$0.01 by +74.72%, while revenue for the quarter reached $1.24M , missing expectations by -25.84%.
Earnings released on 2 Oct 2024
EPS came in at -$0.01 , while revenue for the quarter reached $1.70M .
Earnings released on 25 Sept 2024
EPS came in at -$0.00 , while revenue for the quarter reached $1.36M .
Earnings released on 29 Apr 2024
EPS came in at -$0.01 , while revenue for the quarter reached $826.48K .
Earnings released on 27 Feb 2024
EPS came in at -$0.01 , while revenue for the quarter reached $1.60M .
Earnings released on 30 Sept 2023
EPS came in at -$0.00 , while revenue for the quarter reached $753.71K .
Earnings released on 30 Aug 2023
EPS came in at -$0.01 , while revenue for the quarter reached $810.91K .
Earnings released on 31 Mar 2023
EPS came in at -$0.00 , while revenue for the quarter reached $409.97K .
Earnings released on 31 Dec 2022
EPS came in at -$0.01 , while revenue for the quarter reached $398.86K .
Earnings released on 31 Aug 2022
Earnings released on 30 Aug 2022
EPS came in at -$0.00 , while revenue for the quarter reached $367.32K .
Earnings released on 31 Dec 2021
EPS came in at -$0.01 , while revenue for the quarter reached $167.41K .
Earnings released on 7 Sept 2021
Earnings released on 30 Jun 2021
EPS came in at -$0.01 , while revenue for the quarter reached $94.20K .
Earnings released on 31 Dec 2020
EPS came in at -$0.02 , while revenue for the quarter reached $15.57K .
IMRN Stock Performance
Access detailed IMRN performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.